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Abstract: It has been more than 25 years since HGF was discovered as a mitogen of
hepatocytes. HGF is produced by stromal cells, and stimulates epithelial cell proliferation, motility,
morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor,
c-Met. In fetal stages, HGF-neutralization, or c-Met gene destruction, leads to hypoplasia of many
organs, indicating that HGF signals are essential for organ development. Endogenous HGF is
required for self-repair of injured livers, kidneys, lungs and so on. In addition, HGF exerts protective
eﬀects on epithelial and non-epithelial organs (including the heart and brain) via anti-apoptotic and
anti-inﬂammatory signals. During organ diseases, plasma HGF levels signiﬁcantly increased, while
anti-HGF antibody infusion accelerated tissue destruction in rodents. Thus, endogenous HGF is
required for minimization of diseases, while insuﬃcient production of HGF leads to organ failure.
This is the reason why HGF supplementation produces therapeutic outcomes under pathological
conditions. Moreover, emerging studies delineated key roles of HGF during tumor metastasis, while
HGF-antagonism leads to anti-tumor outcomes. Taken together, HGF-based molecules, including
HGF-variants, HGF-fragments and c-Met-binders are available as regenerative or anti-tumor drugs.
Molecular analysis of the HGF-c-Met system could provide bridges between basic biology and
clinical medicine.
Keywords: HGF, c-Met, regeneration, organ protection, embryogenesis, mesenchymal-
epithelial interaction
1. Discovery of HGF as a hepatotrophic factor
The liver plays diverse roles in the metabolism of
the body and actively regenerates after partial
hepatectomy or during hepatitis. Numerous biolo-
gists attempted to identify a phantom factor that
acts as a trigger for liver regeneration after 70%-
hepatectomy, since cross-circulation experiments in
parabiotic rodents demonstrated that liver regener-
ation is initiated by a blood-born factor. Never-
theless, such a humoral factor was not identiﬁed for
the past more than 30 years, since a simple, sensitive
and reliable in vitro assay system was not available
until the early 1980’s. Several studies, including our
own, revealed that adult rat hepatocytes in primary
culture retained numerous liver-speciﬁc functions and
responded to various hormones.1)–4) This fact encour-
aged us to identify as-yet-unknown hepatotrophic
factor(s) via the establishment of an in vitro assay of
DNA synthesis in adult rat hepatocytes. In this
section, we describe the previous eﬀorts leading to
puriﬁcation and cDNA cloning of HGF.
1-1. The challenge of establishing an in vitro
assay for identifying hepatotrophic factors. In
1983, we demonstrated that adult rat hepatocytes in
primary culture could proliferate at a low cell density
in a medium containing insulin and epidermal growth
factor (EGF),3) providing an experimental tool for
searching hepatotrophic factors. Using this assay
system, we identiﬁed, in 1984, a putative hepato-
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rats. This factor stimulated DNA synthesis and
proliferation of adult rat hepatocytes in primary
culture and we named it as “Hepatocyte growth
factor” or “Hepatotropin”.5) Our in vitro assay system
also contributed to “complete puriﬁcation” of rat
HGF from the platelets of 3,000 rats and revealed
that it was a new growth factor.6),7) This successful
puriﬁcation of native HGF led to the successful
cloning of HGF cDNA as well as to the determination
of the complete amino acid sequences of rat and
human HGF, as described later.
1-2. Chemical properties of HGF. HGF was
puriﬁed to homogeneity from rat platelets using a
four-step procedure including heparin-aﬃnity chro-
matography.6),7) We noticed in 1984 that HGF had
an aﬃnity for heparin-sepharose CL-6B during a
survey of ligands for aﬃnity chromatography of
HGF.5) Consequently, HGF was puriﬁed from rat
platelets to homogeneity in only four steps, resulting
in a high yield.7) Other investigators also used
heparin-aﬃnity chromatography for puriﬁcation of
HGF either from the plasma of patients with
hepatitis8) or from healthy volunteers.9)
HGF has a molecular weight of 84kDa on SDS-
PAGE.7) Under reducing conditions, it gives two
bands with molecular weights of 69kDa and 34kDa,
respectively. Thus, HGF is a dimeric molecule
composed of an ,-subunit (69kDa) and a --subunit
(34kDa), respectively, linked by a disulﬁde bond.
HGF is a heat-labile protein; it loses activity
appreciably when heated to 56°C for 30min or
completely when boiled for 1.5min. Activity is also
partially lost after treatment with acetic acid and
completely lost by trypsin treatment.
1-3. Molecular cloning and primary struc-
ture of HGF. We ﬁrst succeeded in 1988 for partial
cloning of rat HGF cDNA from a liver cDNA library
using the N-terminal sequence of rat HGF --chain.
Northern blot hybridization using rat HGF cDNA
revealed that the size of HGF mRNA was about 6 kb.
Thus, both rat and human HGF cDNA were screened
from the human and rat liver cDNA library using
the rat HGF cDNA as a probe. Finally, full-sized
cDNA of both rat and human HGF were cloned in
1989.10),11) The nucleotide sequence comprises a
single open reading frame of 2,184 nucleotides and
3,580 nucleotides of 3′-non-coding regions. In the
open reading frame, we also conﬁrmed the 19 amino
acid residues of the N-terminus of the ,-subunit for
rat HGF. The C-terminus of the ,-subunit is followed
directly by the N-terminus of the --subunit. The
sequence at the cleavage site between the ,-a n d--
subunit is Arg 494-Val 495, and this site is cleaved by
serine proteases. Overall, HGF is synthesized as a
pro-HGF of 728 amino acids and then mature HGF is
formed by proteolytic cleavage (Fig. 1A). In mature
HGF, Cys 487 in the ,-chain and Cys 604 in the --
chain form an interchain bridge. Human HGF cDNA
was also cloned by Miyazawa et al.12)
1-4. Both scatter factor and tumor cytotoxic
factor are identical to HGF. Scatter factor (SF)
was ﬁrst identiﬁed as a human embryonic ﬁbroblast
(MRC5)-derived protein that enhances motility of
renal tubular cells (MDCK).13) We found that the
motogenic activity of SF was abolished by adding
anti-HGF antibody, while HGF also mimicked the
scatter activity in a culture of MDCK.14) Moreover,
MRC5 cells expressed 6kb mRNA, which was
hybridized with a HGF cDNA probe, and SF cDNA
cloned from the MRC5 cDNA library had the same
sequence as that of cDNA from human leukocytes,
thus eventually indicating that SF is identical to
HGF.14),15)
HGF was originally discovered as a mitogen
of adult rat hepatocytes5)–7) whereas HGF has a
cytotoxic eﬀect on certain tumor cells, such as
hematoma, HepG2.16) With regard to this, Higashio
et al. found that human lung ﬁbroblasts (IMR-90)
secrete a soluble factor capable of killing Sarcoma-
180 and named it tumor cytotoxic factor (TCF). The
chemical properties of TCF were almost similar to
those of HGF. This group isolated TCF cDNA from
the cDNA library of IMR-90 cells. As a consequence,
TCF was found to be molecularly identical to
HGF.17)
1-5. c-Met, an oncogenic gene product, is an
HGF-receptor. While HGF was discovered in the
sera of 70%-hepatectomized rats,5) the c-Met proto-
oncogene product (c-Met) had been identiﬁed as a
new member of the tyrosine kinase family, possibly as
a new receptor of unknown growth factor(s): Bottaro
et al. found in 1992 that c-Met is a receptor for
HGF:18) A 145-kDa tyrosyl phosphoprotein observed
in rapid response to HGF-addition of target cells
was identiﬁed by immunoblots as the --subunit of
the c-Met proto-oncogene product. Furthermore, we
obtained direct evidence that c-Met is bound to HGF
with a high aﬃnity (Kd = 30 pM) after a transfection
of the human c-Met cDNA-carrying plasmid into
COS-7 cells,19) thus identifying the c-met product as
the high-aﬃnity receptor for HGF.
c-Met is composed of a 50kD ,-chain and a
145kD --chain.18) The ,-chain is exposed extracell-
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unit containing an intracellular tyrosine kinase
domain. Binding of HGF to c-Met induces phospho-
rylation of C-terminally clustered tyrosine residues
of tyrosine kinase, which results in biological activi-
ties in a wide variety of cells, including mito-
genic, motogenic and morphogenic activities20)–22)
(Fig. 1B). The biological activities of HGF, required
for restoring organ diseases, are discussed later (see,
section 5).
2. Hepatotrophic roles of HGF
during liver regeneration
Liver regeneration is recognized as an example of
controlled tissue growth.23) Originally, HGF was
identiﬁed in the sera of 70%-hepatectomized rats,
as a mitogen of adult rat hepatocytes.5),20) Indeed,
during hepatic injuries, blood and liver HGF levels
markedly increased, via both extra-hepatic and
intra-hepatic pathways.21),24) Animal studies using
either anti-HGF antibody or c-Met gene destruction
techniques revealed that both the endocrine and
paracrine eﬀects of HGF are involved in liver
growth after 70%-hepatectomy, and for recovery
from hepatitis, respectively.21),25) This concept is
conserved in numerous organs. Herein, we describe
the mechanisms whereby liver regeneration is regu-
lated, through sequential molecular events, focusing
on the function of the HGF-c-Met system.
2-1. Essential roles of HGF for liver growth
after 70%-hepatectomy. There were two-waved
increases of plasma HGF levels in the 70%-hepatec-
tomized rats, which had preceded the initiation of
hepatocyte duplication.24) Northern blot analysis
revealed that HGF mRNA levels had markedly
increased in intact distant organs, such as lungs,
kidneys and spleens, rather than in the remnant
livers, post-70%-hepatectomy.24),26) These studies
were the ﬁrst to imply the importance of the
“endocrine” system for delivering HGF into the
remnant lobes via the portal vein (Fig. 2).
The fact that blood-born HGF triggers liver
regeneration was demonstrated in 1992: when re-
combinant human HGF (rh-HGF) was intravenously
administrated into hepatectomized mice, hepatocyte
duplication was enhanced.27) Inversely, anti-HGF
IgG diminished the regenerative responses (i.e.,
G1/S progression) of hepatocytes after liver inju-
ries.28),29) Such a regenerative role of endogenous
HGF-c-Met was also observed in liver-speciﬁc c-Met-
deﬁcient mice.30) These ﬁndings indicate that the
production of HGF by distant organs (such as lung
and spleen) acts in an endocrine manner to drive liver
regeneration post-70%-hepatectomy.
2-2. HGF-c-Met axis for in situ repair during
acute hepatitis. During hepatitis, destructed areas
of hepatocytes are replaced with neo-generated
hepatocytes, and this regenerative fashion is deﬁned
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Fig. 1. Structure and biological function of HGF. (A) Production and activation of HGF. HGF is produced and secreted as a pro-HGF
by stroma cells such as ﬁbroblasts, macrophages, renal mesangium and so on. Secreted pro-HGF is cleaved at Arg494 and Val495 by
HGF-activators, such as urokinase-type plasminogen activator (uPA). (B) Multi-faceted biological actions of HGF mediated via the
c-Met/HGF-receptor. Binding of HGF to c-Met leads to tyrosine phosphorylation, and each biological activity is elicited via the
recruitment of down-stream adaptor molecules (see, section 4).
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such as carbon tetrachloride (CCl4), induce acute
hepatitis in laboratory animals, which mimics a
pathological status in humans. Using CCl4-treated
rodents as a model for hepatitis, we have accumu-
lated evidence showing that the paracrine system for
the production and delivery of HGF is also required
for recovery from hepatitis (Fig. 2).
In contrast to 70%-hepatectomy, an increase in
HGF mRNA levels is more evident and occurs earlier
in the liver than in distant organs in rats during acute
hepatitis.31) In situ hybridization identiﬁed sinusoidal
cells (including Kupﬀer cells) as the source of HGF
during hepatitis.32) Notably, anti-HGF IgG reduced
the number of proliferating hepatocytes after CCl4-
injection.28) Such a role of the HGF-c-Met axis for
reversing hepatitis is reproducible in liver-speciﬁc
c-Met-knockout mice,30) indicating that the paracrine
signal elaborated from neighboring cells (such as
Kupﬀer cells) is critical for morphological and func-
tional recovery from hepatitis.
2-3. Sensing systems for HGF production
during liver regeneration. HGF is now recognized
as a hepato-regenerative factor during liver injuries.
Thus, it is important to elucidate the mechanism
whereby the host cells produce and deliver HGF to
injured sites in a response that is commensurate with
the type and degree of liver insult. Although the
identiﬁcation of HGF-inducers in the plasma or
injured livers remains to be addressed, several known
molecules are involved in the up-regulation of HGF
gene expression.
For example, pro-inﬂammatory cytokines are
produced by resident or inﬁltrated macrophages in
the injured livers. Among these mediators, inter-
leukin (IL)-1, IL-6, interferon-. and tumor necrosis
factor-, (TNF-,) are involved not only in the
priming of hepatocytes for G0-to-G1 conversion23)
but also in the up-regulation of HGF expression.33)
In other words, inﬂammatory mediators (such as
IL-6/TNF-,) may participate in liver regeneration,
as a co-mitogen for G0/G1 priming (i.e., direct
eﬀect),23) and later, as an inducer of HGF for the
inevitable G1/S progression (i.e., indirect eﬀect)
post-hepatectomy.
Blood hormones and neuro-transmitters may be
involved in the endocrine system of HGF. For
example, growth hormone accelerated liver growth
post-hepatectomy in hypophysectomized rats, and
this was linked with the up-regulation of HGF
production.34) Blood norepinephrine (NE) levels
are increased after 70%-hepatectomy, while ,1-
adrenoreceptor blockers inhibits liver growth. NE
can enhance HGF production in cultured ﬁbro-
blasts,35) thus suggesting an involvement of NE in
liver regeneration. Systemic prostaglandin-E is in-
volved in liver growth post-hepatectomy, while
prostaglandin-E stimulates HGF production,36) sug-
gesting roles of prostaglandins-HGF pathways in
liver regeneration.
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Fig. 2. Critical roles of the HGF-c-Met system during liver regeneration. During liver injury, HGF is produced by distant organs (i.e.,
kidney, lung and spleen) in response to HGF-inducers, such as norepinephrine, growth hormone, prostaglandins and cytokines (i.e.,
endocrine system). Furthermore, HGF is produced in sinusoidal cells, such as Kuppfer cells (i.e., paracrine system). Both systems are
required for compensatory liver growth and in situ repair.
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trigger HGF production in intra-hepatic tissues (i.e.,
as a paracrine loop) and in extra-hepatic organs
(i.e., as an endocrine system). In addition, humoral
mediators, such as neuro-transmitters, hormones and
autacoids may be involved in the endocrine mecha-
nism of HGF production (Fig. 2).34)–37)
2-4. Injury organ-speciﬁc signal transduction
of HGF. An increase in plasma HGF levels means a
systemic exposure of numerous organs to circulating
HGF, but HGF is accumulated predominantly in
injured organs.38) In other words, intact organs can
escape c-Met activation by blood HGF, probably due
to no need for tissue repair, although the molecular
basis of this phenomenon remains unclear. Using an in
vitro assay, we found that a serine residue at position
985 (Ser-985) in the juxtamembrane of c-Met acts as a
negative regulator to limit HGF-c-Met signaling.39)
Under Ser-985-phosphorylated conditions, HGF fails
to induce a scattering of epithelium, while the release
of Ser-985 phosphorylation by protein phosphatase-
2A (PP2A) allowed for c-Met tyrosine phosphoryla-
tion and migration of epithelium.39) Thus, the
reciprocal balance between phosphorylation of Ser-
985 and tyrosine may be a key determinant of HGF-c-
Met signaling—in non-injurious tissues, Ser-985 is
always phosphorylated, which leads to the inhibition
of c-Met tyrosine phosphorylation, even in the
presence of HGF. However, once the tissues undergo
parenchymal injuries, the Ser-985 site is de-phos-
phorylated via recruitment of PP2A. Overall, c-Met
tyrosine is phosphorylated in response to HGF,
leading to the regenerative outcomes (Fig. 3).
3. Regenerative roles of HGF in other organs
Several lines of in vitro studies have revealed
that HGF has regenerative eﬀects on epithelium in
the kidney, lung and other tissues.20),21),25),40) Indeed,
plasma HGF levels are elevated in patients during
organ injuries.41) The administration of anti-HGF
IgG is known to result in the inhibition of epithelial
repair in numerous organs of rodents. Based on these
data, we emphasize the common mechanism of HGF
for tissue repair in many organs, such as the kidney,
as follows.
3-1. Renal regeneration. As with the liver,
compensatory growth occurs in remnant kidneys
after partial nephrectomy in adaptation to a loss in
the number of nephrons. Although the existence of
blood-born renotrophic factors has been implicated,
these factors remain to be identiﬁed. Prior to the
initiation of renal regeneration, HGF mRNA and
protein levels increase in remnant kidneys and intact
organs (such as lungs),42),43) thus suggesting that
paracrine and endocrine mechanisms of HGF are
involved in renal regeneration. We found in 1994 that
exogenous HGF increased the number of regenerat-
ing tubular cells in the right kidney after a left
nephrectomy.44) Renal growth is also observed after
unilateral ureter-ligation (UUO), along with the
c-Met
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Fig. 3. A hypothetical model for injury-speciﬁc HGF/c-Met intracellular signaling. (A) In non-injurious (i.e., normal) organ tissues, a
serine residue site at position 985 (Ser-985) in the juxtamembrane of c-Met is constitutively phosphorylated and functions as a
negative regulator to inhibit HGF-Met signaling (i.e., switch OFF). (B) Once organ tissues undergo injuries, Ser-985 site is
“de-”phosphorylated, probably via recruitment of intracellular PP2A. As a result, c-Met tyrosine sites are phospholylated, and then
pleiotropic activities are delivered (i.e., switch ON).
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IgG decreased the proliferating tubular cells,45) thus
indicating that UUO-induced renal growth is medi-
ated, in part, via the HGF-c-Met system.
In addition to compensatory growth, HGF is
required for in situ repair during acute renal failure
(ARF). In the mid-1990s, we found that adminis-
tration of rh-HGF enhanced tubular regeneration in
mice treated with renal toxins.43),44) In the mid-
2000’s, we demonstrated, using a model of ischemic
ARF, that endogenous HGF is important for main-
taining renal homeostasis46),47): there was a two-
waved increase (i.e., 1 and 24 hours) in plasma HGF
levels after renal ischemia. Notably, anti-HGF IgG
antibody enhanced tubular apoptosis in the early
stage of ARF46) and inhibited the proliferation of
tubular cells in the later stage,47) thus indicating that
endogenous HGF is anti-apoptotic and mitogenic for
protection and recovery from ARF, respectively.
3-2. Lung regeneration. Following acute lung
injury in rodents, HGF mRNA and protein levels
apparently increased within 24 hours after the
challenge, and then lung alveolar and bronchial
epithelium entered into a G1/S-stage.48) Further-
more, exogenous HGF administration enhanced mito-
genesis in the lung airways and alveoli of mice after
lung injury.49) Direct evidence showing a contribution
of endogenous HGF was demonstrated in two studies
using rodent models.50),51) Transient lung ischemia led
to alveolar destruction in rats, while alveolar repair
became evident 4 days post-ischemia, and was
associated with an increase in HGF production.50)
Notably, anti-HGF IgG treatment diminished alveo-
lar cell proliferation in a rat model of ischemia.50)
The same results were obtained in a mouse model of
lobectomy, where compensatory growth of lungs was
impaired by anti-HGF IgG.51) These studies clearly
demonstrated a major role for endogenous HGF
during lung repair and growth—even in adulthood.
3-3. Mucosal repair in gastro-intestines. In
gastro-intestinal organs, mucosal membrane is
always exposed to chemical and mechanical stress
during the digestion and absorption of foods. Thus,
the aﬀected mucosa must be quickly repaired via
movement of daughter epithelial cells. Exogenous
HGF accelerates the healing of gastric injuries.52),53)
By contrast, the inhibition of c-Met activation by
anti-HGF IgG in the gastric mucosa suppressed the
proliferation and movement along of the folds of
the mucosal epithelial cells.53) As a result, gastric
mucosal integrity continued to be impaired under
HGF-neutralized conditions. Similar results were
seen in a mouse model of colitis, where the mucosal
injuries were aggravated and accompanied by a
decrease in c-Met tyrosine phosphorylation.54) In
the gastro-intestinal tissues, HGF is constitutively
produced by stromal cells in the sub-mucosa, while
c-Met is over-expressed on the mucosal epithelium.
Such a paracrine loop serves as a molecular surveil-
lance system to avoid ulcer formation.
3-4. Physiological roles of HGF in other
organs. The local HGF-c-Met systems are involved
in not only tissue repair but also in metabolic
homeostasis. HGF stimulates mitogenesis and insulin
production in pancreatic --cells.55) HGF is produced
by ,-cells and regulates insulin production in --cells
to prevent hyperglycemia.55) Importantly, --cell-
speciﬁc ablation of c-Met resulted in a reduction
of islet size, a decrease in blood insulin levels, and
eventually onset of mild hyperglycemia in mice.56)
These ﬁndings indicate that local HGF-c-Met system
is required for control of blood glucose levels.
HGF is required for self-repair after the injuries
of skin, muscle and cartilage; anti-HGF IgG dimin-
ished the proliferation and migration of keratinocytes
during wound healing in mice.57) In addition,
HGF-c-Met signaling is responsible for hair follicle
morphogenesis and cycling in skin.58) During muscu-
lar damage, HGF is produced by myogenic cells
(i.e., autocrine pathway). When anti-HGF IgG was
injected into mice during a muscular damage,
myoblast duplication and muscular ﬁber formation
were suppressed.59) HGF is a mitogen of chondro-
cytes in vitro and attenuates the cartilage damage in
rabbit knees.60)
HGF is also required for hematopoiesis. We
found that HGF promotes the proliferation and
colony formation of hematopoietic progenitors in
vitro.61),62) In a line of HGF-transgenic mice, platelet
counts were increased,63) probably via enhancement
of thrombopoietin production in hepatocytes. Of
note, hepatic hematopoiesis is impaired in c-Met-
deﬁcient fetal mice.64)
In summary, endogenous HGF is important for
inducing self-repair responses in numerous organs
(Table 1). The paracrine or endocrine pathway that
is predominantly involved in tissue repair depends on
the degree, or kind, of injury.20),25) Regardless of the
pathway, HGF is secreted as a pro-HGF and then
converted to the active form only at the injury sites
by HGF-activators.21),41) This local activation system
may explain the injury-speciﬁc c-Met activation that
elicits a regenerative response only in an injured
organ.
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epithelial interaction for organ development
During organ development, proper proliferation
and morphogenesis of epithelial cells proceeds to form
most organs, via inductive interactions with the
mesenchyme: organogenesis is initiated when the
resident epithelium interacts with speciﬁc mesenchy-
mal tissues at deﬁned stages of development, result-
ing in organ-speciﬁc structures and functions. Such a
pararine loop may provide clues that will allow
development of new strategies for regenerative
medicine. Thus, it is critical to identify the mesen-
chymal mediators during organogenesis.
HGF has multiple biological functions, required
for generation, development and maturation of
Table 1. Importance of endogenous HGF-c-Met system during organ regeneration or homeostasis
Organ and injury Treatment (Animals) Outcomes Ref. no
Liver:
Compensatory growth 70%-hepatectomy (c-Met-KO mice) Suppression of hepatocyte proliferation,
Lipidosis
Huh-CG et al. [30]
Acute hepatitis CCl4 + Anti-HGF IgG (Mice) Suppression of hepatocyte proliferation,
Retard repair
Burr-AW et al. [28]
Cholestasis BDL + Anti-HGF IgG (Mice) Suppression of hepatocyte proliferation,
Enhanced liver failure
Li-Z et al. [29]
Kidney:
Ischemic ARF Renal I/R + Anti-HGF IgG (Mice) Suppression of tubular epithelial cell
proliferation,
Ohnishi-H et al. [47]
Enhanced apoptosis, Accelerated ARF Mizuno-S et al. [46]
Obstructive
nephropathy
UUO + Anti-HGF IgG (Mice) Suppression of tubular epithelial cell
proliferation, Accelerated ﬁbrosis
Mizuno-S et al. [45]
Nephrotic syndrome ICGN mouse strain + Anti-HGF IgG Suppression of tubular epithelial cell
proliferation, Accelerated ﬁbrosis,
Enhanced TGF-- production
Mizuno-S et al. [91]
Lung:
Compensatory growth Lobectomy + Anti-HGF IgG (Mice) Suppression of alveolar and bronchial
proliferation
Sakamaki-Y et al. [51]
Ischemic injury Lung I/R + Anti-HGF IgG (Rats) Suppression of alveolar cell proliferation Yamada-T et al. [50]
Heart:
Myocardial infarction Heart I/R + Anti-HGF IgG (Rats) Enhanced apoptosis, Accelerated cardiac
failure
Nakamura-T et al.
[95]
Stomach:
Gastric erosion Cisplatin + Anti-HGF IgG (Mice) Inhibition of gastric cell proliferation Nakahira-R et al. [53]
Intestine:
Colitis 3%DSS + HGF-A-KO (Mice) Weight loss, Death, Inhibited mucosal
repair
Itoh-H et al. [54]
Pancreatic islets:
Glucose metabolism --cell spaciﬁc c-Met-KO (Mice) Hypoplasia of islets, Decrease in blood
insulin
Dai-C et al. [56]
Skin:
Wound healing Surgical wound + Anti-HGF IgG
(Mice)
Retarded repair, Accelerated granuloma Yoshida-S et al. [57]
Muscles:
Myotitis Cardiotoxin + uPA-KO (Mice) Decrease of regenerating ﬁbers, Enhanced
damage
Sisson-TH et al. [59]
c-Met-KO, c-Met gene knockout; BDL, Bile duct ligation; I/R, Ischemia and reperfusion; uPA-KO, uPA gene knockout; HGF-A-KO,
HGF-activator gene knockout; TGF--, Transforming growth factor--; DSS, Dextran sodium sulfate. For other abbreviations see text.
T. NAKAMURA and S. MIZUNO [Vol. 86, 594parenchymal organs, as shown in Fig. 1B. HGF is
expressed mainly by mesenchymal cells, while c-Met
is identiﬁed on the parenchyma during organo-
genesis,20),65),66) suggesting that HGF-c-Met signals
play an essential role in mammalian and non-
mammalian developments. This hypothesis was
demonstrated in numerous tissues of rodents or
Xenopus (Table 2).
Needless to say, mitogenesis, motogenesis, and
“morphogenesis (i.e., 3M-activities) all are essential
for organogenesis. HGF was identiﬁed as a hepato-
cyte mitogen,5) and SF/HGF was described as a
motogen of epithelial cells.13) Fibroblast-derived
condition medium was found in 1991 to induce
formation of blanching tubules in epithelial cells
(MDCK) in collagen gels; this activity was abolished
Table 2. Importance of HGF-c-Met signaling during organ development and maturation
Treatment (Species) Outcomes References
Liver:
HGF-KO (Mice) Embryonic lethal, Loss of hepatocytes,
Loss of hematopoiesis
Schmidt-C et al. Nature 373: 699 (1995)
c-Met dominant negative (Xenopus) Aplasis / Hypoplasia Aoki-S et al. BBRC 234: 8 (1997)
Kidney:
Organ culture + Anti-HGF IgG
(Mice)
Meta-nephric growth retardation,
Mesenchyme-to-epithelium transition
inhibition
Barros-EJ et al. PNAS 92: 4412 (1995)
c-Met dominant negative (Xenopus) Pronephron hypoplasia Aoki-S et al. BBRC 234: 8 (1997)
Lung:
Organ culture [E13] + Anti-HGF IgG
(Mice)
Inhibition of branching and tubulogenesis Ohmichi-H et al. Development 125: 1315
(1998)
c-Met-KO [E18.5] (Mice) Suppression of alveolar formation Yamamoto-H et al. Dev. Biol. 308: 44 (2007)
Newborn [P3-P6] + Anti-HGF IgG
(Rats)
Inhibition of secondary crest formation,
Loss in alveoli
Padela-S et al. Am. J. Respir. Crit. Care Med.
172: 907 (2005)
Gut:
c-Met dominant negative (Xenopus) Aplasia/Hypoplasia Aoki-S et al. BBRC 234: 8 (1997)
Muscle:
c-Met-KO (Mice) Limb bud hypoplasia, Diaphragm hypoplasia Bladt-F et al. Nature 376: 768 (1995)
Nerve tissues:
Organ culture + anti-HGF IgG
(Rats)
Inhibition of motoneuron axon outgrowth Ebens-A et al. Neuron 17: 1157 (1996)
Mu-c-Met-KI (Mice) Inhibition of limb innervation,
Defect of spinal cord branching
Maina-F et al. Genes Dev. 11: 3341 (1997)
Post-neonate [P3-14] + anti-HGF
IgG (Rats)
Inhibition of OPC proliferation, Ohya-W et al. Brain Res. 1147: 51 (2007)
Teeth:
Organ culture (E14) + HGF-AS
(Mice)
Decrease of proliferating enamel epithelium Tabata-MJ et al. Development 122: 1234
(1996)
Mammary gland:
HGF-gene transfection (Mice) Enhancement of hyperplastic
ductual branching
Yant-J et al. Exp. Cell Res. 241: 476 (1998)
Hematopoietic tissue:
c-Met dominant negative (Xenopus) Decreased expressions of GATA-1,
SCL and ,-globin
Koibuchi-N et al. Blood 103: 3320 (2003)
Placenta:
HGF-KO (Mice) Trophoblast loss (aplasia) Uehara-Y et al. Nature 373: 702 (1995)
HGF-KO, HGF gene knockout; Mu-c-Met-KI, Mutated c-Met gene knock-in; HGF-AS, HGF antisense oligodeoxy-nucleotide; OPC,
oligodendrocyte progenitor cell; SCL, stem cell leukemia. For other abbreviations see Table 1 and text.
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gen.67) The diﬀerential selection in 3M-activities
was due to a diﬀerence in adaptor molecules, which
are recruited by tyrosine-phosphorylated c-Met. For
example, phosphorylated-tyrosine-dependent recruit-
ment of the Grb-2-SOS complex activates Ras
and ERK, leading to migration.22) In contrast, the
association and tyrosine phosphorylation of Gab-1, a
docking protein that couples c-Met with multiple
signaling proteins (such as PI-3K, PLC and Shp-2),
leads to morphogenesis and cell movement.68) These
variations explain the multi-functional activities of
HGF.
Organ development and regeneration may share
a common molecular program, especially during
morphogenesis. Thus, developmental studies stimu-
lated researchers to determine the role of HGF during
migration, proliferation and conversion of stem cells
to mature functional cells under diseased conditions.
Gaining a better understanding of the HGF-medi-
ated pathways would provide a conceptual bridge
between developmental biology and regenerative
medicine.
5. Roles of the HGF-c-Met system
during organ diseases
Since HGF-c-Met system is essential for tissue
regeneration in adulthood, we hypothesized that
organ failure might occur as a result of either
“HGF-deﬁciency” or “HGF-insuﬃciency”.25),40) Thus,
an understanding of HGF-induced biological func-
tions is helpful for comprehending the mechanism
whereby HGF supplementation attenuates life-
threatening disorders. Prior to discussion of the
therapeutic eﬀects of HGF, we summarize the
multi-faceted functions of HGF that are required
for improving organ dysfunction under pathological
conditions.
5-1. Anti-apoptotic and function-promoted
roles of HGF. Apoptotic events are one of the key
pathogenic causes for the manifestation of organ
injury. HGF prohibits apoptotic signals via inhibition
of caspase-3 activity or induction of anti-apoptotic
molecules, such as Bcl-xL.69),70) Furthermore, HGF
prohibits Fas-mediated apoptosis signals via seques-
tration of Fas and c-Met on cell surfaces.71) These
eﬀects of HGF protect the epithelium, neurons
and cardiomyocytes during organ diseases (see,
section 6). Furthermore, HGF enhances the organ-
speciﬁc functions that are required for maintenance
of local metabolism. For instance, HGF enhances
albumin synthesis and lipid metabolism in hepato-
cytes,72),73) Na+-K+-ATPase expression in renal
tubules,40) and insulin production in --cells.55) These
eﬀects lead to both maintenance of homeostasis and
functional recovery during diseases.
5-2. Anti-ﬁbrogenic performance of HGF.
During chronic organ injuries, TGF-- plays a pivotal
role in tissue ﬁbrosis via converting HGF-produc-
ing ﬁbroblasts to ECM-producing myoﬁbroblasts
(MyoFBs).25),40) HGF inhibits TGF-- production in
cultures of MyoFBs74),75) and intercepts the TGF-
-1-mediated signal pathway by inhibiting nuclear
smad2/3 activation.76) Moreover, HGF reduced the
TGF---receptor77) and induced decorin, an inhibitor
of TGF--1,78) all of which might lead to anti-ﬁbrotic
outcomes in vivo (see, section 6.2). In addition, HGF
inhibits the functions of other ﬁbrogenic cytokines,
including platelet-derived growth factor (PDGF),
connective tissue growth factor (CTGF) and mono-
cyte chemoattractant peptide-1 (MCP-1). HGF
inhibits PDGF-mediated over-proliferation of
MyoFBs,79) reduces CTGF-induced scarring,80) and
inhibits MCP-1-mediated inﬂammation during the
HGF-mediated attenuation of ﬁbrosis. HGF induced
matrix metalloprotease (MMP) in MyoFBs.81),82)
Induction of MMP by HGF is required for not
only ECM degradation but also for elimination of
MyoFBs, both of which contribute to resolution of
ﬁbrosis, as discussed later.
5-3. Anti-inﬂammatory action of HGF to-
ward immune cells. During organ injuries, local
or systemic inﬂammation is a common pathway
that leads to tissue destruction. In this process,
leucocytes (such as neutrophils, eosinophils and
macrophages) are key players in accelerating inﬂam-
mation. HGF inhibits neutrophil inﬁltration via
the down-regulation of adhesion molecules (such as
ICAM-1/E-selectin) on the endothelial cell surface,46)
which suppresses ischemia-related injury in various
organs.29),47),83) Moreover, HGF directly targets
activated eosinophils and prohibits their migration
via down-regulation of inﬂammatory mediators dur-
ing allergic inﬂammation.84)
Activated macrophages elicit inﬂammatory
events via release of pathogenic regulators, such as
IL-1, IL-6 and IL-18. HGF suppressed the produc-
tion of these cytokines via recruitment of anti-
inﬂammatory regulators, such as heme oxygenase-1
(HO-1).85) Moreover, HGF stimulated diﬀerentiation
of macrophages into immunosuppressive dendritic
cells (DC),86) which facilitate induction of regulatory
T-lymphocytes, a key player in anti-inﬂammation
during immunological challenge.87) Thus, such con-
T. NAKAMURA and S. MIZUNO [Vol. 86, 596certed regulations by HGF may explain the attenu-
ation of immunogenic diseases, as mentioned in
section 6-3.
5-4. Angiogenic action of HGF toward vas-
cular cells. Under pathological conditions, hypoxia
elicits apoptosis in endothelial and epithelial cells,
while a decrease in local vessels further accelerates
ischemic organ dysfunction. HGF is an angiogenic
factor in vitro,88) in addition to vascular endothelium
growth factor (VEGF) and basic ﬁbroblast growth
factor (b-FGF). Induction of angiogenesis by HGF
supplementation resulted in improved local hypo-
xia.89) HGF had an anti-apoptotic eﬀect on endothe-
lium via Bcl-2 induction.70) In contrast to other
angiogenic factors, HGF has beneﬁts, such as anti-
thrombosis.90) VEGF enhanced endothelial perme-
ability and edema, whereas HGF inhibited endothe-
lial permeability.46),90) In contrast to the ﬁbrotic
eﬀects of b-FGF, HGF is anti-ﬁbrotic. These beneﬁts
lead to “therapeutic angiogenesis”, even under hy-
poxic conditions.89)
5-5. Critical part of the intrinsic HGF-c-Met
system during chronic organ diseases. Systemic
and local HGF levels are increased during chronic
diseases,25),40),41) but those levels are not higher than
in the case of acute diseases. Nevertheless, when an
anti-HGF antibody was administered to mice with
nephrotic syndrome, tubular injury and renal ﬁbrosis
became evident, associated with a reciprocal increase
in TGF-- levels.91) The similar results were also
observed during diabetic nephropathy and hydro-
nephrosis in mice.45),75) Bile duct ligation (BDL) is
known to induce liver ﬁbrosis, and there was an
apparent ﬁbrotic lesion post-BDL in the liver after
the liver-speciﬁc deletion of c-Met in mice.92) Thus,
we emphasize that the transient increase of HGF is
necessary for minimization of tissue ﬁbrosis, while the
loss in HGF production allows for tissue dysfunction
during chronic diseases.
5-6. Mechanisms for the down-regulation of
HGF during persistent injuries. Given that
various diseases become severer as a result of HGF-
deﬁciency, how HGF production is impaired is a
central interest of pathologists. Under conditions of
persistent injury, TGF-- and angiotensin-II were
shown to suppress HGF gene expression in vitro,25),89)
and the levels of these factors gradually increased
in vivo, in response to chronic injury. In addition,
hypoxia and hyperglycemia also repressed HGF
production both in vitro and in vivo.89),93) Thus,
it is likely that pathogenic factors (i.e., TGF--,
hypoxia and high-glucose) successfully establish
tissue ﬁbrosis via down-regulating HGF production.
In summary, HGF has various actions that
counteract pathological events during organ dam-
ages. According to the sequence of pathogenic events,
each HGF-mediated biological signal is, step-by-step,
involved in protection, repair, anti-inﬂammation and
anti-ﬁbrosis. How HGF elicits these activities de-
pends on microenvironment conditions in real-time,
such as apoptosis, scarring and ischemia. Such a
dynamic change is still of interest to biologists and
has led to an understanding of HGF-mediated
therapeutic outcomes, as mentioned below.
6. Therapeutic signiﬁcance of HGF for
the rescue of intractable diseases
Although the HGF-c-Met axis functions as a
self-defense and self-repair system, the increase in
HGF production is transient, insuﬃcient and often
retarded, resulting in progression of organ failure.
Thus, we predicted that re-induction of this repair
system by supplementation of HGF might be a
strategy to attenuate organ disease.20),21) This initial
hypothesis is now being demonstrated worldwide in
animal models of various diseases, in which either
recombinant HGF or the HGF gene is administered,
as follows.
6-1. Acute diseases. (1) Fulminant hepatitis:
Viral infection of hepatocytes is the major cause of
fulminant hepatitis. Activated T-cells eliminate
virus-infected hepatocytes via the Fas-mediated
pathways to prohibit viral replication, but over-
elimination of liver cells leads to lethal hepatic
failure. A Fas-agonist (Joe2) elicits massive hepato-
cyte apoptosis in mice that is similar to human
fulminant hepatitis. Using this model, we found that
HGF prevents a lethal outcome: hepatic destruction
became massive within 8 hours post-Joe2-treatment,
associated with hepatocyte apoptosis. By contrast,
injections of rh-HGF prohibited the onset of hepatic
destruction (Fig. 4A).69) In this process, HGF in-
duced Bcl-xL, an anti-apoptotic molecule, in hepato-
cytes within 2 hours after the Joe2 injection.69)
Overall, HGF blocked hepatic apoptosis and failure
in the Joe2-treated mice.
(2) Acute renal failure (ARF): ARF is charac-
terized by a rapid loss of renal function and electro-
lyte abnormalities, which occur due to a defect in
tubular integrity, especially around the S3-segments
of proximal tubules. Of note, rh-HGF elicits tubular
repair and accelerates recovery from renal dysfunc-
tion in rodent models of ARF, induced by ischemia,
cisplatin or cyclosporine-A.40),44),94) Early injections
The impact of HGF discovery on medical sciences No. 6] 597of rh-HGF inhibit the onset of ARF via anti-
inﬂammatory eﬀects on renal endothelium.46) In
septic mice, HGF markedly attenuated the progres-
sion of ARF, via inhibiting systemic inﬂamma-
tion and coagulations, both are critical for septic
organ failure.85) As a result, rh-HGF was shown
hopeful to decrease the mortality rate during sepsis
(Fig. 4B).
(3) Acute lung injury (ALI): Aspiration pneu-
monia is the most common respiratory complication
among elderly humans, and is due to impairments of
swallowing and of the cough reﬂex. In a mouse model
of aspiration pneumonia, rh-HGF stimulated DNA
synthesis in the airway and alveolar cells.49) Likewise,
rh-HGF prevented the onset of ALI, caused by
sepsis,85) or by transient ischemia.83) Given that HGF
production becomes insuﬃcient in elderly patients,48)
HGF-treatment may be reasonable for prevention or
reversal of ALI, including pneumonia.
(4) Myocardial infarction (MI): Acute MI is now
the leading cause of death in developed countries,
and is due to an interruption of the blood supply
by atherosclerosis of the coronary vessels. Under
hypoxic conditions, the myocardium becomes apop-
totic, followed by ventricular dysfunction. We found
that rh-HGF targets the myocardium and intercepts
apoptotic signals via the induction of Bcl-xL in a rat
model of MI.95) As a result, cardiac apoptosis and
the loss of ventricular dysfunction were prevented
(Fig. 4C). In the same year, Aoki et al. reported that
local induction of angiogenesis by HGF cDNA led to
improved outcomes during acute MI.96) Overall, HGF
was found to improve acute MI via myocardial
protection and angiogenesis.
6-2. Chronic diseases. (1) Fibrotic diseases:
Liver cirrhosis is an irreversible end result of scarring
during chronic injury via the loss of hepatocytes, and
is associated with a high mortality. HGF is over-
expressed by sinusoidal cells at an early stage of
alcoholic hepatitis, along with hepatocyte prolifer-
ation, but its expression is reduced near ﬁbrotic
areas.97) In vitro, HGF induced uPA,98) which is
critical for the degradation of ECM (extra-cellular
matrix). Based on this background, we obtained the
ﬁrst evidence that HGF reversed cirrhotic lesions,99)
caused by dimethyl nitrosamine (DMN) in rats. In
this model, ECM-degrading enzymes were increased
by HGF, leading to the disappearance of ECM
and hepatocyte repair (Fig. 5A). As a result, HGF
improved the lethal outcomes.99) The same eﬀects
were seen in other models that diﬀered in the initial
cause of cirrhosis.25),100)
Chronic kidney disease (CKD) is incurable,
except through renal transplantation. Dialysis mar-
ket estimates indicate that more than two million
patients worldwide have undergone dialysis, and the
number of patients with CKD is on the rise. Renal
ﬁbrosis represents the morphological equivalent of
end-stage CKD. Using mouse models of nephrotic
syndrome, we found in 1998 that rh-HGF is useful for
restoring renal dysfunction via induction of tubular
repair, down-regulation of TGF-- production, and
resolution of ﬁbrosis (Fig. 5B).101) The same eﬀects
were also seen in mouse models of hydoronephrosis
and diabetic nephropathy.45),75)–77)
Lung ﬁbrosis is a reﬂection of interstitial
pneumonia. MyoFB hyperplasia leads to over-depo-
sition of ECM, which then impairs alveolar regener-
ation. This pathological circuit further aggravates
lung ﬁbrosis. HGF has anti-ﬁbrotic eﬀects during
bleomycin-induced lung injury in mice (Fig. 5C).102)
Using the same model, we found that HGF induces
apoptosis in MyoFBs via an indirect mechanism:
HGF-induced MMP-9 degrades ﬁbronectin, an essen-
tial anchor that maintains cell survival.81) As a result,
MyoFBs became apoptotic, along with a decrease in
the matrix anchors. The enhancing eﬀect of HGF on
MyoFB elimination is critical for the resolution of not
only lung ﬁbrosis but also of liver cirrhosis82),103) and
arterial sclerosis.104)
Growing evidence shows that HGF elicits the
regression of ﬁbrosis in numerous organs, such as
scleroderma,105) cardiomyopathy,74) vocal scarring
and peritoneal ﬁbrosis, in which TGF---induced
MyoFBs are critical for tissue scarring. The resolu-
tion of ﬁbrosis provides an open space for repair of
the epithelium and endothelium, resulting in recov-
ery from organ failure.81)
(2) Obstructive diseases: Conservative estimates
predict that chronic obstructive pulmonary diseases
(COPD), including emphysema, will become the
third-leading cause of death by the year 2020.
Emphysema is characterized by the disappearance
of alveolar septa, and widespread destruction of the
pulmonary vascular beds. Since HGF is a morphogen
of alveolar cells49) and endothelial cells,88) HGF is
expected to attenuate emphysema-related patholog-
ical events.106),107) Shigemura et al. reported that
HGF levels in lung tissue and plasma from rats
suﬀering from elastase-induced emphysema increas-
ed, and then declined to below basal levels.107)
Administration of HGF cDNA to the emphysema-
tous rats resulted in more extensive pulmonary
vasculatures and increased proliferation of alveolar
T. NAKAMURA and S. MIZUNO [Vol. 86, 598epithelial cells, which, in turn, improved exercise
tolerance and gas exchange.107) Thus, the decrease in
local HGF levels is responsible for emphysema, while
HGF supplementation can be an option for treating
COPD, associated with induction of alveologenesis
and angiogenesis.
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Fig. 5. Eﬀects of HGF on resolution of tissue ﬁbrosis. Therapeutic supplementation with HGF leads to resolution of (A) liver cirrhosis
(blue signals in Mason-Trichrome stain), (B) renal sclerosis (brown signals in Type-I collagen stain), (C) lung ﬁbrosis (blue signals in
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parenchymal epithelial cells would begin to proliferate, eventually leading to recovery from organ failure.
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Fig. 4. Therapeutic eﬀects of HGF on acute diseases. (A) Inhibition of the onset of fulminant hepatitis by HGF. Hepatic failure was
induced by administration of a Fas-agonist (Joe2) in mice. In this model, HGF almost completely blocked the Joe2-induced hepatic
destruction, as estimated by serum ALT (alanine aminotransferase) levels (left) and histological ﬁndings (hematoxylin and eosin
staining) (middle). Overall, HGF inhibited the lethal outcomes (right). (B) Prevention of septic ARF by HGF-treatment. LPS
induced severe renal damage in mice, associated with loss of the apical brush border (arrowheads in PAS staining), while rh-HGF
blocked apical damage. Likewise, HGF suppressed the increase in blood urea nitrogen (BUN) levels, which was obvious in the saline-
treated septic mice. As a result, HGF-treatment improved the sepsis-related lethal outcome. (C) Preventive eﬀects of HGF on acute
MI in rats after transient cardiac ischemia. HGF-treatment inhibited apoptosis of cardiomyocytes, as evaluated by TUNEL staining.
Likewise, HGF prevented cardiac destruction, as evidenced by serum CPK (creatinine phosphokinase).
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animal models of other obstructive diseases, such as
peripheral artery disease (PAD). A decrease in HGF
production in the hind limbs due to hypoxia
worsened the loss of vascular density and hypoxia,
while a local injection of rh-HGF improved hypoxia
via induction of angiogenesis in a rabbit model
of PAD.89) Under these HGF-insuﬃcient condi-
tions, compensation for the loss of HGF by rh-HGF
supplementation improved local hypoxia and dys-
function, via the enhancement of angiogenesis during
PAD.89)
It is important to note that hypoxia suppresses
HGF production,47),89) while c-Met is over-expressed
in response to hypoxia via activation of a transcrip-
tional factor, HIF-1. Thus, obstructive diseases
become severe due to hypoxia-induced HGF-deﬁ-
ciency, but its receptor is increased, due to the need
for ligand HGF (i.e., SOS sign). This explains the
reason why HGF improves obstructive diseases—
even under persistent hypoxia.
6-3. Inﬂammatory and immunogenic dis-
eases. HGF is critical for tissue protection during
inﬂammatory diseases, via direct action on macro-
phages, DCs or lymphocytes (i.e., an immunogenic
cell-based mechanism) (Fig. 6A). HGF also protects
organs from immunogenic challenge via anti-apop-
totic eﬀects on epithelial cells (i.e., epithelium-
targeted mechanism), as mentioned above. Both
mechanisms lead to therapeutic beneﬁts under
inﬂammatory states, as follows.
(1) Systemic inﬂammatory response syndrome
(SIRS): SIRS occurs during septic infection, leading
to the onset of multiple organ dysfunction syndromes
(MODS). The progression of MODS is programmed
by sequential increases in cytokines, such as IL-1,
IL-6 and IL-18 (i.e., the cytokine storm), which are
released from the activated macrophages. Using a
mouse model of SIRS, we found that rh-HGF
targeted macrophages and inhibited the production
of IL-1, IL-6 and IL-18.85) Overall, the onset of
MODS was inhibited by HGF. This is the ﬁrst report
to show that HGF acts directly on macrophages to
inhibit SIRS, a life-threatening disease.
(2) Asthma: Bronchial asthma is a clinical
syndrome associated with allergen-induced airway
hyper-responsiveness (AHR), which is characterized
by an inﬂux of activated eosinophils and T-lympho-
cytes. Several cytokines (such as IL-5 and IL-13)
play critical roles in orchestrating the allergic
response to AHR. Ito et al. demonstrated that HGF
attenuates allergen-induced AHR in a mouse model
of asthma,84) via suppressing eosinophil and lympho-
cyte accumulation in the airways. Furthermore,
local IL-5 and IL-13 levels were reduced in HGF-
treated asthmatic mice. As a result, the increase
in lung contractile elements was inhibited by HGF-
treatment.108) Thus, HGF may be useful as an
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Fig. 6. Anti-inﬂammatory and neurotrophic actions by HGF for the attenuation of various diseases. (A) Direct eﬀects of HGF on DC or
macrophages (M?). HGF inhibits production of inﬂammatory cytokines, including IL-6, while anti-inﬂammatory regulators (such as
HO-1) are up-regulated, leading to anti-inﬂammatory outcomes. (B) HGF-induced protective eﬀects on various neurons. These
functions are mediated via inhibiting neural cell death, and enhancing neurite outgrowth-axon extensions. (C) Such pleiotropic
functions produce therapeutic outcomes in rodents against various diseases. Left: Inhibitions of leukocyte attack by HGF in the lungs
after allergic challenges. Middle: Preventive eﬀects of HGF on the mucosal injuries of intestines in mice during GVHD. Right:
Maintenance of spinal cord moto-neurons by HGF-transgene in ALS-manifested mice.
T. NAKAMURA and S. MIZUNO [Vol. 86, 600inhibitor of asthma via suppressing cytokine expres-
sion (Fig. 6C).
(3) Immune tolerance after transplantation: The
ﬁrst evaluation of the counter-regulatory role of HGF
during immunogenic challenge involved a rat model
of renal allograft:109) 4-week-injection of rh-HGF led
to the acceptance of a renal allograft between two
rat strains (F344-to-Lewis), even when co-treatment
with cyclosporine-A and rh-HGF was stopped.109)
Strikingly, the renal allograft functioned well for >6
months with no medical treatment, suggesting that
HGF has the potential to induce immune tolerance.
Likewise, the inhibition of ischemic injury by rh-HGF
resulted in the heart graft acceptance.110) Using
mouse models of bone marrow transplantation,
Kuroiwa et al. found that HGF is useful for inhibiting
graft-versus-host-disease (GVHD) (Fig. 6C).111) In
this process, HGF lowered TH1-cytokines that trigger
graft rejection, such as IFN-., while the local levels of
TH2-cytokines, including IL-10, were increased. Such
a reciprocal regulation may be the key mechanism
whereby HGF induces immune tolerance after organ
transplantations.
(4) Auto-immune diseases: The next question
concerns the direct eﬀect that HGF has on immune
cells such as lymphocytes and DCs. Recent studies
have addressed this question. Futamatsu et al. found
that a myosin-challenge increased the c-Met-positive
population of CD4-positive lymphocytes during auto-
immune myocarditis.112) When rh-HGF was added to
the culture of CD4-positive cells obtained from the
diseased rats, myosin-induced proliferation of CD4-
positive cells was inhibited. Furthermore, HGF
increased the levels of IL-4 and IL-10 and decreased
IFN-. levels in vitro as well as in vivo. As a result,
HGF restored cardiac function in the rat with
myocarditis.112) In addition to lymphocytes, HGF
also has suppressive eﬀects on DCs. Using a mouse
model of rheumatoid disease, Okunishi et al. found
that HGF suppressed the production of immuno-
reactive cytokines, such as IL-17, IL-23 and IFN-.
in DCs, leading to the attenuation of rheumatoid
arthritis.113) These results suggest that HGF sup-
presses the over-reaction by immunocytes, possibly
via regulation of pathogenic cytokines.
6-4. Neural diseases. Since mature neurons
cannot duplicate in response to neural injury, it is
important to maintain their survival and stimulate
neurite outgrowth in living neurons for attenuating
neural diseases. HGF has survival-promoting activity
in the neurons of hippocampus, cortex and spinal
cords (Fig. 6B).114)–116) Over-expression of HGF-gene
prolongs the life span of mice during amyotrophic
lateral sclerosis (ALS) via neurotrophic and anti-
inﬂammatory mechanisms.116) These studies led to
extensive evaluations of HGF to improve various
neural diseases, as follows.
(1) Cerebral infarction (CI): CI remains the
third-leading cause of death in developed countries.
The neuro-protective eﬀects of HGF in vivo were ﬁrst
shown in a gerbil model of acute CI.117) Learning and
memory dysfunction were also prevented by early
injections of rh-HGF into the brains of microsphere-
embolized rats.118) However, post-diagnosis treat-
ment is more practical after the onset of CI.
Shimamura et al. found that delayed treatment of
CI using a local HGF gene transfer led to functional
recovery in rats, even under cerebral artery occlu-
sion.119) In this model, HGF enhanced neurite
extension, maintained synapses and increased the
vessels around the infarct region, thus suggesting the
potential of HGF as a new drug to treat CI.
(2) Neuro-degenerative disease (ND): ND con-
stitutes a set of pathological events originating from
slow, irreversible and systematic cell loss within
various regions of the brain and the spinal cord.
HGF-gene delayed the progression of ALS in mice
(Fig. 6C),116) and this eﬀect was reproducible when
rh-HGF was locally administered in a rat model of
ALS.120) Parkinson’s disease is caused by a loss of
dopaminergic neurons in the substantia nigra. In a
rat model of Parkinson’s disease, local HGF gene
transfer protected the dopaminergic neurons from a
6-hydroxydopamine (6-OHDA) challenge, followed
by the improvement in the rotational asymmetry.121)
Furthermore, HGF might be also useful for treat-
ment of Alzheimer’s disease. Indeed, Takeuchi et al.
found that HGF gene transfer alleviated amyloid---
induced cognitive impairment in mice, as evaluated
by a behavioral test.122)
(3) Spinal cord injury (SCI): SCI is damage to
the spinal cord that results in a loss of function such
as mobility or feeling. Frequent causes of damage
include trauma (car accident, gunshot, etc.) and
diseases (polio, spina biﬁda, Friedreich’s ataxia, etc.).
Using a rodent model of SCI, Kitamura et al.
reported that HGF gene administration into injured
spinal cords promoted neuron and oligodendrocyte
survival.123) Furthermore, angiogenesis and axonal
re-growth were also accelerated by HGF. Overall,
functional recovery was evident in the HGF-treated
rats after SCI.
(4) Others: Emerging evidence indicates that
HGF promotes the proliferation of neurospheres
The impact of HGF discovery on medical sciences No. 6] 601Table 3. Therapeutic eﬀects of recombinant HGF protein or HGF cDNA on intractable diseases
Target disease Animal model HGF-treatment Outcocmes References
Liver:
Acute hepatitis ANIT (Mouse) rh-HGF, 30µg/mouse, iv Enhanced regeneration Ishiki-Y et al. [27]
Fluminant hepatitis Fas-agonist (Joe2)
(Mouse)
rh-HGF, 100µg/mouse, ip Inhibition of hepatic failure,
Anti-apoptosis
Kosai-K et al. [69]
Fatty liver Ethanol intake (Rat) rh-HGF, 200, 800µg/kg, iv,
2 weeks
Anti-lipidosis, Increase in
apolipoprotein-B
Tahara-M et al. [73]
Liver cirrhosis Dimethyl nitrosamine
(Rat)
rh-HGF, 300µg/kg, iv,
4 weeks
Improved survival, Regeneration,
Resolution of chirrhosis
Matsuda-Y et al. [99]
Liver ﬁbrosis Bile duct ligation (Rat) Naked HGF cDNA, bolus iv
(hydrodynamics)
Attenuation of ﬁbrosis, Inhibited
myoﬁbroblastosis
Xia-JL et al. [100]
Kidney:
Acute tubular injury HgCl2, Cisplatin (Mouse) rh-HGF, 250µg/kg, iv,
3 days
Tubular protection and repair,
Improvement in renal dysfunction
Kawaida-K et al. [44]
Septic acute renal failure Lipoporisaccharide
(Mouse)
rh-HGF, 500µg/kg, sc, Prevention of cytokine storm,
Improvement in renal dysfunction
Kamimoto-M et al. [85]
Nephrotic syndrome ICGN mouse (tensin-2
mutation)
rh-HGF, 500µg/kg, sc,
4 weeks
Resolution of ﬁbrosis, Repair,
Improvement in renal failure
Mizuno-S et al. [101]
Diabetic nephropathy Streptozotocin-treated
Mouse
rh-HGF, 500µg/kg, sc,
4 weeks
Reduced albuminuria, Inhibition of
glomerular injuries
Mizuno-S et al. [75]
Lung:
Acute lung injury Hydrochloric acid (Mouse) rh-HGF, 10µg/kg, iv, 3 days Re-alveologenesis, Bronchial repair Ohmichi-H et al. [49]
Pulmonary ﬁbrosis Bleomycin (Mouse) rh-HGF, 280µg/mouse,
pump sc, 14 days
Anti-ﬁbrosis, Regeneration Yaekashiwa-M et al. [102]
Pulmonary emphysema Elastase (Rat) HVJ-HGF cDNA, lung
artery injection
Re-alveologenesis, Improvement in
hypo-ventilation
Shigemura-N et al. [107]
Asthma Ovalbumin (Mouse) rh-HGF, 500ug/kg sc,
3 weeks
Up-regulation of TH2 cytokines,
Anti-allergic eﬀect
Ito-W et al. [84]
Heart:
Myocardial infarction Ligation and reperfusion
(Rat)
rh-HGF, 160µg/kg, iv Cardio-protection, Anti-apoptosis,
Improved cardiac function
Nakamura-T et al. [95]
Cardiomyopathy Mutant (TO-2 hamster) rh-HGF, 1mg/kg, sc,
3 weeks
Anti-ﬁbrosis, Anti-apoptosis,
Improved cardiac function
Nakamura-T et al. [74]
Heart transplantation Allograft (Mouse) rh-HGF, 500µg/kg, sc,
2 weeks
Immune tolerance, Anti-ﬁbrosis,
Anti-inﬂammation
Yamaura-K et al. [110]
Autoimmune myoarditis Myosin challenge (Rat) HVJ-HGF, intra-cardium Improvement in cardiac dysfunction,
Anti-inﬂammation
Futamatsu-H et al. [112]
Nervous system:
Brain ischemia Transient ischemia
(Gerbil)
rh-HGF, 10, 30µg/gerbil
(local pump)
Inhibition of CA1 neuron death Miyazawa-T et al. [117]
Cerebral infarction Embolism (Rat) rh-HGF, 30µg/week/rat
(local pump)
Improvement in learning and
memory, Anti-apoptosis
Date-I et al. [118]
Spinal cord injury Trauma (Rat) HSV1-HGF cDNA Local Improvement in learning and
memory, Anti-apoptosis
Kitamura-M et al. [123]
ALS SOD(G93A)-Transgenic
mouse
HGF-transgene
(Neuron-speciﬁc)
Preserved motoneurons, Prolonged
life span
Sun-W et al. [116]
Parkinson’s disease 6-OHDA (Rat) Naked HGF cDNA Local Preserved dopaminergic neurons,
Improved behavior
Koike-H et al. [121]
Alzheimer’s disease Amiroid-- (Mouse) Naked HGF cDNA Local Improvement in memory, Increased
vessel density
Takeuchi-D et al. [122]
Hearing impairment Kanamycin (Rat) HVJ-HGF cDNA Local Improvement in hearing,
Anti-apoptosis
Oshima-K et al. [125]
Gastro-intestines:
Stomach ulcer Cryoplobe injury (Rat) rh-HGF, 500µg/kg, sc Enhanced mitosis Schmassmann-A et al. [52]
Host-versus-graft disease Bone marrow
transplantation (Mouse)
HVJ-HGF cDNA, im
(endocrine)
Repair, Anti-apoptosis,
Anti-inﬂammation
Kuroiwa-T et al. [111]
Skin:
Hindlimb ischemia Surgical ligation (Rabbit) rh-HGF, 500µg/kg, arterial
injection
Enhanced angiogenesis, Improved
hypoxia
Morishita-R et al. [89]
Scleroderma Bleomycin (Mouse) HVJ-HGF cDNA, im
(endocrine)
Anti-ﬁbrosis, Anti-inﬂammation Wu-MH et al. [105]
Panreas:
Type-1 diabetes mellitus Streptozotocin (Mouse) Naked HGF cDNA, bolus iv
(hydrodynamics)
Improved hyperglycemia, Prevention
of --cell destruction
Dai-C et al. [55]
rh-HGF, recombinant human HGF; ANIT, ,-naphthylisothiocyanate; HVJ-HGF, hemagglutinating-virus-of-Japan liposome
containing HGF cDNA; sc, subcutaneous injection; iv, intravenous injection; ip, intraperitoneal injection. For other abbreviations,
see Tables 1, 2 and text. Other indications of HGF supplement therapy are summarized in our current review articles.25),40),41)
T. NAKAMURA and S. MIZUNO [Vol. 86, 602and neuronal diﬀerentiation of neural stem cells.124)
Thus, HGF may induce neurogenesis during neural
diseases. In kanamycin-treated deaf rats, delayed
administration of HGF cDNA restored hearing loss,
the most prevalent sensory deﬁcit in humans.125)
HGF also shows promise for attenuating various
neural diseases, including diabetic neuropathy126) and
multiple sclerosis.87)
In summary, HGF improves acute and chronic
organ diseases via its regenerative, anti-apoptotic,
and anti-ﬁbrotic eﬀects. HGF is useful for attenuat-
ing inﬂammatory disorders via direct eﬀects on
immune cells. Moreover, HGF improves neural
diseases, associated with the promotion of axon
outgrowth and enhancement of neuronal survival.
The multiple eﬀects of HGF lead to the attenuation
of intractable organ diseases (Table 3).
7. Summary and perspective
It has been 21 years since the cloning of human
HGF cDNA was successfully performed.10) In the
past two decades, the biological functions of the
HGF-c-Met axis have been extensively examined,
and the crucial physiological and therapeutic roles of
stroma-derived HGF have been demonstrated during
organogenesis and recovery from diseased conditions.
The central focus of physiologists had been on
epithelium, myocardium and neurons, since they
are functional. On the other hand, cell biologists
suggested an important function of stromal cells
based on the results of in vitro experiments; actually,
ﬁbroblasts were used as a feeder cell to support
epithelial cell growth, motility and morphogenesis in
vitro. HGF is now known as a key molecule among
the stroma-derived mediators. This may be the
reason why stroma has a “casting vote” to support
homeostasis, although the amount of stroma is much
less than that of the parenchyma.
Given that organ failure is deﬁned as “HGF-
deﬁciency” disease, HGF supplementation is reason-
able as a pathogenesis-based therapeutic strategy
(Fig. 7). The successful cloning of HGF cDNA
facilitated the mass-production of recombinant
HGF. Indeed, growing evidence indicates that
recombinant HGF, or HGF cDNA, is feasible as a
drug to prevent or reverse a variety of diseases. Based
on previous experimental outcomes, clinical trials of
HGF in patients (phase-I/II) are now ongoing in
Japan, the United States and China. For example,
a local injection of HGF cDNA-carrying plasmids
HGF
* Parenchymal growth 
* Anti-apoptosis 
* ECM degradation
Compensatory phase
TGF−β β
HGF
De-compensatory phase
* ECM production 
* Apoptosis 
* Growth inhibition
TGF−β β
Recombinant HGF  
(or HGF gene)
TGF−β β
HGF
Inhibition / Reverse
* Resolusion of Fibrosis 
* Epithelial Repair 
* Stem Cell Recruitment 
* Recovery from loss-of-function
HGF
Supplement
of Organ Dysfunctions
Fig. 7. Pathogenesis and treatment of organ failure by HGF. Reciprocal balance between HGF and TGF-- is involved in determining
the prognosis of chronic organ diseases, such as liver cirrhosis, renal sclerosis and lung ﬁbrosis. In the early stages of chronic disorders,
HGF production is enhanced to suppress TGF--1 production. When HGF dominates the balance, regenerative and anti-ﬁbrotic
events occur as a compensatory response. By contrast, TGF-- production is up-regulated during the advanced stages to prohibit HGF
production. Under TGF---dominant conditions, a loss in regenerative power leads to a rapid progression of organ ﬁbrosis and
dysfunction. To reverse the pathogenic balance, HGF supplementation should be considered as a new strategy for the attenuation of
ﬁbrosis (and gliosis), a common pathway leading to end-stage organ failure in liver, kidney, lung, heart and possibly the nervous
system as well.
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PAD127),128) and cardiac artery diseases (CAD),129)
without adverse eﬀects. In addition, rh-HGF has
shown promise to attenuate hepatitis and skin ulcers
in patients.130),131) The safety and eﬃcacy of rh-HGF
is also being tested in patients with renal diseases.
HGF is also involved in cancer invasion and
metastasis. The discovery of NK4 as an HGF-
antagonist has promoted research in cancer biology,
pathology and therapy.132)–134) The mechanism
whereby stromal cells over-produce HGF for accel-
erating tumor malignancy has been investigated, and
HGF-inducers (such as autacoids and cytokines)
have been identiﬁed. Growing evidence indicates
that NK4 inhibits tumor growth, invasion and
metastasis in rodents bearing various types of
malignant tumors.133),134) It has been shown that
over-activation of c-Met, due to either genetic
mutation(s) or over-stimulation by HGF, in lung
carcinoma elicits resistance to EGF-receptor kinase
inhibitors (i.e.,G e ﬁnitib), while NK4-therapy alle-
viated this resistance in rodents,135) suggesting the
promising use of NK4 for the rescue of Geﬁnitib-
resistant tumors. Overall, NK4-related studies have
led to the emerging concept that the HGF-c-Met
pathway is a key target for inhibiting tumor
malignancy. Several approaches to inhibit HGF-c-
Met signaling are now being developed as an anti-
cancer agent: using small molecules that inhibit
c-Met tyrosine kinase activation, ribozymes, siRNA,
anti-HGF IgG, and soluble c-Met.133)
Given that HGF is critical for organo-protection,
regeneration and tumor malignancy under patho-
physiological conditions, we predict that HGF-based
molecules, such as HGF-variants, HGF-chimera,
HGF-fragments and c-Met-binders show promise
as part of a new arsenal in the ﬁght to suppress
organ failure and tumor malignancies. Treating these
diseases with either HGF or new HGF-based drugs
may be more reality than dream.
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